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Is Urinary Sodium a Surrogate Marker of
Plasma Brain Natriuretic Peptide in ST
Elevation Myocardial Infarction ?
Januar W Martha, Hariadi Hariawan, Taofan S, Nani Hersunarti,
Bambang B Siswanto
Background. High level of Brain Natriuretic Peptide (BNP) was suspected
as a predictor of adverse events in acute ST Elevation Myocardial Infarc-
tion (STEMI). Unfortunately, the cost and availability of BNP assay had
hampered its use. Natriuresis is one of the hallmark effect of raised BNP
and measuring urinary sodium might offer insight to the plasma BNP. This
study aims to search for any correlation between measured plasma BNP
and urinary sodium in patients presenting with acute STEMI.
Methods. In an observational descriptive analytic study, we selectively in-
cluded patients presenting with acute STEMI and checked for plasma BNP
and urinary sodium. All patients had no symptoms or therapy of heart
failure prior to admission, had no prior MI, had no valvular abnormalities,
and had normal renal function. Plasma BNP was tested using immunoassay
method from Abbot Diagnostics, while urinary sodium with ionic specific
electrode method. Specimen for plasma BNP were taken at the admission
while urinary sodium in the next morning, taking account of urine volume.
Results. There were 17 patients, 15 were (82.4%) men, with age 55.1+8.2
years old, onset of STEMI 18.6+2.3 hours, and left ventricular ejection
fraction (LVEF) 47.6+11.6%. The urinary sodium was 85.1+34.3 mEq/L,
and plasma BNP 449.7+48.8 pg/ml. Pearson’s correlation and linear re-
gression analysis showed positive correlation between urinary sodium and
plasma BNP (r = 0.71). In multivariate analysis, plasma BNP (p<0.01) and
LVEF (p<0.05) were the major influencing factors for urinary sodium level.
Conclusion. This study revealed a strong correlation between plasma BNP
and urinary sodium in patients presenting with acute STEMI. While mea-
surement of urinary sodium cannot replace plasma BNP, it might actually
reflect plasma BNP level.
(J Kardiol Ind 2007; 28:19-26)
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Latar belakang: Kadar Brain Natriuretic Peptide (BNP)  yang tinggi diduga
merupakan prediktor kejadian buruk pada infark miokard akut dengan elevasi
ST (ST Elevation Myocardial Infarction  - STEMI). Akan tetapi pemeriksaan
BNP mahal dan tidak mudah didapat, sehingga penggunaannya terbatas.
Natriuresis merupakan salah satu efek menonjol dari kenaikan BNP, sehingga
kemungkinan pengukuran kadar Natrium dalam urin dapat menggambarkan
kadar BNP plasma. Penelitian ini bertujuan untuk melihat hubungan antara
kadar BNP plasma dan kadar Natrium urin pasien STEMI akut.
Metoda. Penelitian ini merupakan studi analitik deskriptif observasional.
Secara selektif disertakan pasien STEMI akut, kemudian diperiksa kadar
BNP plasma dan Natrium urin. Semua pasien tak mempunyai keluhan atau
mendapat terapi gagal jantung ketika masuk perawatan, juga belum pernah
mengalami infark miokard sebelumnya, tak ada kelainan katup, dan fungsi
ginjalnya normal. Kadar BNP plasma diukur menggunakan metoda immu-
noassay dari Abbot Diagnostics, sedangkan kadar Natrium dalam urin diukur
dengan metoda ionic specific electrode. Sampel darah untuk mengukur BNP
plasma diambil saat pasien masuk perawatan, sedangkan Natrium urin
diukur keesokan harinya, mengingat diperlukan waktu untuk mendapat urin
yang cukup jumlahnya.
Hasil. Ada 17 pasien yang memenuhi kriteria, 15 (82.4%) laki-laki, dengan
usia 55.1+8.2 tahun, onset STEMI 18.6+2.3 jam, dan fraksi ejeksi ventrikel
kiri (LVEF) 47.6+11.6%. Kadar Natrium urin 85.1+34.3 mEq/L, dan BNP
plasma 449.7+48.8 pg/ml. Analisis hubungan Pearson  dan regresi linier
menunjukkan korelasi positif antara Natrium urin dan  BNP plasma (r = 0.71).
Pada analisis multivariat, terbukti bahwa BNP plasma (p<0.01) dan LVEF
(p<0.05) merupakan faktor utama yang mempengaruhi kadar Natrium urin.
Kesimpulan. Penelitian ini telah membuktikan adanya hubungan kuat antara
BNP plasma dengan Natrium urin pada pasien-pasien STEMI akut. Meskipun
pengukuran Natrium urin tak dapat menggantikan BNP plasma, namun
sebenarnya dapat merefleksikan kadar BNP plasma.
(J Kardiol Ind 2007; 28:19-26)
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The cardiac natriuretic peptide system is activated af-
ter AMI.1,2  Morita et al.3 were the first to demon-
strate significantly elevated plasma Brain Natriuretic
Peptide (BNP) levels on admission in 50 patients with
ST-elevation acute myocardial infarction (STEMI)
compared with controls, with peak levels were observed
16 h after onset. BNP is released by the ventricles as a
neurohormonal response to increased wall stress and
pressure and volume overload.4,5 In a subsequent study,
increase plasma BNP secretion may more accurately
reflect regional wall stress in the infarcted region of
the ventricle.6 Increased regional wall stress is believed
to be associated with adverse ventricular remodeling
and a poor prognosis after STEMI.7,8
BNP has a spectrum of pharmacological activities
such as diuretic, natriuretic, hypotensive, and smooth
muscle relaxant activities and inhibition of the renin-
aldosterone axis.9,10 These effects are due to the stimu-
lation of guanylate cyclase–linked natriuretic peptide
receptors, leading to an increase in cGMP concentra-
tion in target cells.10,11 The site of action of BNP is
assumed at many level of nephron, including proxi-
mal and distal tubules as well as the inner medullary
collecting duct. Figure 1 shows the effect of BNP which
increase intracellular cGMP level  that leads to inhibi-
tion of sodium transport across cell.11
From a clinical perspective, evidence of close re-
lation-ship between plasma BNP level and urinary
sodium excretion is shown by a study done by La
Villa et al.12 They showed that acute incremental in-
crease of plasma BNP level in normal individuals re-
sulted in increase in urinary sodium excretion in a
placebo-controlled, crossover study. Their study in-
volved six healthy volunteers who received incremen-
tal infusions (0.25 pmol/kg per minute in the first
hour and 0.50 pmol/kg per minute in the second) of
synthetic human brain natriuretic peptide-32. BNP
administration induced a significant 1.7-fold increase
in urinary sodium excretion without affecting renal
plasma, glomerular filtration rate and urine flow rate.
Urinary sodium level showed an approximate 52%
increase during the lower BNP dose (0.25 pmol/kg
per minute) and a further 12% increment during the
higher dose (0.50 pmol/kg per minute) as shown in
figure 2. The cumulative increase in urinary sodium
excretion induced by BNP infusion was therefore
70%.12
In addition to increase urinary sodium excretion,
BNP also exerted an inhibitory effect on the renin-
aldosterone axis, as indicated by the significant 50%
or more decrease of plasma renin activity and urinary
excretion rate of aldosterone. These results suggest that
BNP may be involved in the overall regulation of body
fluid and cardiovascular homeostasis in humans.12 In
conclusion of all the above literature reviews, it is
theoritically plausible that the level of urinary sodium
is correlated with the level of plasma BNP in a clinical
setting.
There are problems perceived with BNP labora-
tory test. First is the cost of the BNP assay. Since all
BNP assay available in Indonesian market is imported,
the cost of laboratory examination is high. One labo-
ratory test for BNP will cost Rp 200.000,- or more
depending on the assay used. In Indonesia or in any
low income countries, this amount of money is sub-
stantial. For many patients especially those who are
Figure 1. The mechanism of sodium transport inhibition
by natriuretic peptides in inner medullary collecting duct.11
GC-A – guanylate cyclase A, GC-B – guanylate cyclase B,
PKG – protein kinase G, CNG - cyclic nucleotide-gated
cation channel, NKA– Na+, K+-ATPase, AA – arachidonic
acid, PGE2 – prostaglandin E2, ANF – atrial natriuretic
factor, BNP – Btype natriuretic peptide, URO – urodilatin,
CNP – C-type natriuretic peptide.
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not covered with insurance or patients who their in-
surance will not reimburse BNP test, the amount of
money incurred for BNP test may be better allocated
to purchase medications. Second problem is the avail-
ability of BNP assay. At least for now, laboratory test
to measure plasma BNP level can only be performed
in large medical laboratory or in provincial hospital.
While importance of BNP assay has already recognized,
district (kabupaten) hospital should be given oppor-
tunity to take full advantage of this new test. Further-
more, the problem of availability of BNP assay may
have underlying laboratory resources deficiency within
the district hospital, either the assay itself, equipment
or manpower. Considering these two present prob-
lems with plasma BNP assay, the reasearchers were
looking for any alternative but less costly laboratory
test that has significant correlation with plasma BNP.
One candidate laboratory test is urinary sodium, not
only because it physiologically increased when plasma
BNP is elevated as shown by previous literature, but
also urinary sodium test costs only one-tenth of plasma
BNP test. But in order to use urinary sodium as an
alternative to plasma BNP, their correlation in clinical
patients should be determined. On academic ground,
it was surprising enough that there were no published
literature (using Medline, Highwire and other docu-
ment searches) demonstra-ting the correlation between
plasma BNP and urinary sodium in the setting of clini-
cal STEMI patients. These two arguments: problems
of BNP assay and no previous study relating urinary
sodium and palsma BNP in a clinical setting signify
our rationale for conducting this study. Therefore the
objective of this study is to search for any correlation
between plasma BNP and urinary sodium in patients
presenting with STEMI.  Further validation of their
correlation would be supported by looking for factors
that influence urinary sodium level in patients pre-
senting with STEMI.
Methods
The design of this study was observational descriptive
analytic, recruiting patients presenting with  STEMI.
The study was conducted during 3 months period
(between November 2005 through  January 2006) at
National Cardiovascular Center “Harapan Kita”
Jakarta. Patients were selected at admission, either in
the emergency department or in the intensive cardio-
vascular unit.
Selection of patients was based on the predeter-
mined inclusion criteria, which are: no symptoms/
signs and or therapy of heart failure prior to admis-
sion, no prior MI, no valvular abnormalities, and nor-
mal renal function. Symptoms of heart failure include
exercise intolerance, dyspnea on exertion, orthopnea,
paroxysmal nocturnal dyspnea, peripheral edema. Signs
of heart failure was verified by the presence of
cardiomegali, S3, basal pulmonary rales, elevated jugu-
lar pulse, hepatomegaly and leg edema. Therapy of
heart failure may consist of ACE inhibitors, diuretics,
beta blockers, digoxin. But for the majority of patients,
medical record was the main source for the determi-
nation of heart failure prior  to admission.  Prior MI
proved  to  increase  BNP  level13 and  it  was deter-
mined by searching previous history from medical
record or by looking at evidence of  pathologic  Q
wave  on the 12-lead electrocardiography. Transthoracal
echo-cardiography was performed in all patients on
the day 3 - 4 of hospitalization where left ventricular
ejection fraction was recorded. Any significant (more
than trivial) valvular abnormalities was noted and pa-
tients with significant valvular regurgitation was ex-
cluded.
Figure 2. Increase urinary sodium excretion after adminis-
tration of BNP.12 Line graphs show mean (solid line) and
individual (dashed lines) values of UNaV in the three clear-
ance periods performed during administration of placebo
and BNP (1=baseline, 2=0.25 pmol/kg per minute, 3=0.50
pmol/kg per minute).
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Determination of patients selected to be recruited
in the study was done by 2 researchers working inde-
pendently, and all patients who fulfill the inclusion
criteria was recruited consecutively. Patients selected
were then recorded with regards to their age, sex, on-
set of STEMI, risk factors (especially hypertension and
diabetes mellitus), infarct location, and other impor-
tant characteristics including previous drugs that has
been consumed.
Plasma BNP level was determined at admission or
at the earliest time after being selected, using immu-
noassay method from Abbot Diagnostics. Overnight
urine was collected using standard collection method
at the intensive cardiovascular unit and checked for
urinary sodium in the next morning. Overnight urine
was used as the collection protocol due to previous
study by Kamata et al14 and Tsai et al15 that showed
overnight urine was easy and reliable for the estima-
tion of sodium excretion for 24 hours. Overnight urine
was also chosen because of practicality and simplicity
of specimen collection compared with the standard
24 hours urine collection. Urine volume of each pa-
tients were also recorded. Urinary sodium level was
determined using ionic specific electrode method.
Aside of plasma BNP and urinary sodium, all patients
was also examined for plasma sodium, plasma creati-
nine, plasma ureum, plasma glucose as a routine labo-
ratory examination.
Overnight therapy for STEMI patients was veri-
fied for any diuretics or high dose ACE inhibitors,
since these two drugs may interfere sodium excretion
in the urine. High dose ACE inhibitors was loosely
defined as Captopril 3x25 mg or more, or its equiva-
lent dosage with other ACE inhibitors. Patients who
received these drugs were also excluded.
 Descriptive statistics (proportion, mean, standard
deviation), Pearson correlation and multiple regres-
sion analysis were used for analysis, using software
SPSS for Windows v.10 and Statistica  foe Windows
v.6.
Result
There were a total of 78 STEMI patients during 3
months period, starting from November 2005 to
January 2006. Using the above inclusion criteria,
we selectively recruited 24 patients (54 were ex-
cluded). Seven out of these 24 patients were further
excluded due to their overnight therapy which con-
sisted of diuretics or high dose ACE inhibitors, leav-
ing the remaining 17 patients as  study  subjects.
Only  one  patient  had trivial mitral regurgitation
on transthoracal echocardiography hence all of these
17 patients represent the final sample population
for this study.
Table 1 shows several important characteristics of
study subjects. Some interesting points in this table
are the onset of  STEMI which had a wide variation
that may cause difference in the plasma BNP concen-
tration. Although mean onset of STEMI in our study
was 18 hours which was an ideal time to measure
plasma BNP concentration (peak level achieved at 16
hours of onset), earlier onset relates to lower plasma
BNP level.
Hypertension and diabetes mellitus are well-known
risk factors that have impact on left ventricular dias-
tolic function. Reduced diastolic function also increase
plasma BNP level shown by previous studies.16, 17 This
study incorporated  high proportion of hypertensive
patients which may have elevated baseline plasma BNP
level.
Slightly more than 50% of our patients under-
went coronary revascularisation, either by throm-
bolytic or percutaneus coronary intervention.
Group analysis comparing urinary sodium and
plasma BNP in patients with or without coronary
revascularisation would be interesting but we did
not perform group analysis because of small sample
population.




Age (years) 55 + 8.2
Onset STEMI (hours) 18 + 13.4
Sex:  - Male 14 82.4
 - Female 3 17.6
Hypertension 10 58.8
Diabetes mellitus 6 35.3
Infarct: - Anterior 7 41.3
- Inferior 8 47
- Both 2 11.7
Revascularization:
- Thrombolytic 5 29.4
- PCI 4 23.5
LV Ejection Fraction (%) 47 + 11.6
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Plasma BNP levels were substantially higher in
patients with STEMI than normal value (less than 100
pg/mL). This finding conforms with previous obser-
vation by Morita et al.3 As predicted, this high plasma
BNP concentrations correspond to the increase in uri-
nary sodium level (normal value less than 40 mEq/L
for overnight urine). Other laboratory values are not
remarkable. Some patients, in particular diabetics, had
increase plasma glucose level. As has been known, high
plasma glucose level will affect urinary volume and
thus urinary sodium concentration.
This study produced a significant correlation co-
efficient between plasma BNP and urinary sodium.
The regression line with 95% confidence interval was
shown (Figure 3). Although the coefficient is high, it
would probably be difficult to apply this result in the
population of STEMI patients as the sample popula-
tion is too small. Larger sample may decrease this co-
efficient correlation, in accordance of the statistical
theorem of regression toward the null.
Although the researchers exercise effort on mini-
mizing confounding factors by applying quite strict
inclusion criteria,  several  variables  may  still  poten-
tially affect the plasma BNP level and therefore uri-
nary sodium level. Multiple regression analysis was
chosen to check which variables acts as confounding
factors for urinary sodium level. This method was per-
formed by selecting urinary sodium as the dependent
variables and the following factors as the independent
variables: age, hypertension, diabetes, infarct location,
onset, plasma glucose,  plasma BNP, LVEF, plasma crea-
tinine, and plasma sodium. This analysis was also car-
ried out to reveal the most important variables that
affect urinary sodium. Table 3 shows two statistically
significant variables that influence urinary sodium
level.
The result of multivariate analysis further confirm
the existence of relationship between plasma BNP and
urinary sodium. As only two variables: plasma BNP
and left ventricular ejection fraction determine uri-
nary sodium level, other possible factors that may in-
fluence urinary sodium level is statistically excluded.
It has been recognized that plasma BNP increase when
Figure 3. Correlation between plasma BNP and urinary sodium
Table 2. Laboratory values
Laboratory Mean + SD
Plasma sodium (mEq/L) 139 + 3.7
Plasma creatinin (mg/dL) 1.0 + 0.3
Plasma glucose (mg/dL) 186.5 + 54
Plasma BNP (pg/mL)  449 + 48.8
Urinary sodium (mEq/L) 85 + 34.3
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left ventricular ejection fraction is significantly reduced,
reflecting left ventricular volume or pressure overload.
We speculate that in our patients, low ejection frac-
tion works by raising plasma BNP level and the latter
will eventually increase urinary sodium concentration.
Discussion
This study utilized an observational, descriptive ana-
lytic design. In this kind of study, careful attention
must be paid to limit the confounding factors which
may interfere with the results of the study. Therefore
the researchers set rigid inclusion criteria which hope-
fully can ward off any possible confounding factors.
As a result of these inclusion criteria, the number of
patients who could be recruited was low and might
have influenced the power of this study. This approach
was selected in the view of better validity at the ex-
pense of low study power. Low powered study increased
type B error and the end result might be overestima-
tion of the true population value, in this case the coef-
ficient correlation. Larger patients recruitment is the
only solution to the low powered study.
Several factors such as sodium and water intake,
hydration status, inaccuracy of urine collection, and
ingestion of certain drugs might cause error in the
determination of urinary sodium level. Moreover, there
might be differences in the above factors among pa-
tients and homogenous population of patients could
not be achieved. The researchers realized that it might
be extremely difficult to reach homogeneity of patients
for this study since sodium and water intake prior to
admission is virtually impossible to control. But even
in a well designed, randomized study, water and so-
dium intake prior to admission of STEMI patients is
difficult to control. Controlled study has the advan-
tages of comparison with different population which
can confirm the findings of the study. Control popu-
lation of normal individuals might have different
plasma BNP level compared to STEMI patients. If
there exists a correlation between plasma BNP and
urinary sodium in the control population, it can fur-
ther confirm the existence of association between
plasma BNP and urinary sodium. This study was lack-
ing of control population due mainly to financial re-
sources.
 The results of this study has to be interpreted care-
fully that it could only be applied to a specific subset
of STEMI patients. These specific patients are those
without preexisting heart failure or those without
therapy for heart failure. In patients with preexisting
heart failure, plasma BNP level has already high and
thus urinary sodium excretion will increased. Therapy
of heart failure consists of ACE inhibitors, with or
without diuretics. These two class of drugs cause higher
sodium excretion in the urine. The same reasons  also
true   for  patients   with  previous   myocardial infarc-
tion which may have increased plasma BNP level on
the background. Renal failure intervene sodium han-
dling of the kidney and causes increase or decrease
sodium reabsorbtion in the proximal and distal tu-
bules, and therefore the results of this study could not
be applied in patients with renal insufficiency
The clinical implications of the demonstration of
statistically significant associations between these two
laboratory tests depend not only on the strength of
the association but also on practical aspects of the as-
say, such as the stability of the substance to be mea-
sured and the applicability and versatility of the bio-
chemical analysis in question. We believe that sodium
in the urine is relatively stable under normal condi-
tion hence its concentration is reliable to measure. On
the practical point of view, the only hassle to measure
urinary sodium is the collection of urine.
On the positive side, this study represent the first
to address association between plasma BNP and uri-
nary sodium in clinical STEMI patients. It would be
imperative that this research can encourage further
research in this field with more sample and control in
order to verify our findings.
Conclusion
We found a strong correlation between plasma BNP
and urinary sodium in a specific subset of patients
presenting with STEMI. Measurement of urinary so-
dium might actually reflect plasma BNP level, but
whether urinary sodium can be a surrogate marker for
plasma BNP need to be further validated.
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